• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    TransCode Therapeutics, Inc. - Common Stock (NQ:RNAZ)

    1.770 +0.060 (+3.51%)
    Delayed Quote Updated: 4:00 PM EDT, Oct 23, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 32,683
    Open 1.650
    Bid (Size) 1.670 (100)
    Ask (Size) 1.830 (300)
    Prev. Close 1.710
    Today's Range 1.650 - 1.840
    52wk Range 1.520 - 13.96
    Shares Outstanding 833,683
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    NetworkNewsBreaks – TransCode Therapeutics, Inc. (NASDAQ: RNAZ) to Present Updated Phase 1a TTX-MC138 Clinical Data at ESMO Congress 2026
    Via Investor Brand Network
    BioMedNewsBreaks — TransCode Therapeutics, Inc. (NASDAQ: RNAZ) Reports Updated Phase 1a Data for TTX-MC138 in Advanced Solid Tumors
    Via Investor Brand Network

    Performance

    52-Week Range 87.3% below 52-week high
    1.770
    1.5252W Low 13.9652W High
    1 Week 3.8% below 1-week high
    1.601W Low 1.841W High

    TransCode Therapeutics, Inc. - Common Stock (RNAZ) traded between $1.52 and $13.96 over the past 52 weeks and last traded at $1.77, 87.3% below its 52-week high. Over the past week it ranged between $1.60 and $1.84.

    Past 12 Months
    +4.1%
    +5.4%
    -70.2%
    -79.2%
    -76.1%
    -86.5%
    1W +$0.07
    1M +$0.09
    3M -$4.16
    6M -$6.75
    YTD -$5.63
    1Y -$11.37

    RNAZ was -86.5% over the past year, -79.2% over six months, -76.1% year to date, +4.1% in the last week.

    12 Months vs Market
    RNAZ
    -86.5%
    DIA
    +11.6%
    SPY
    +13.1%
    QQQ
    +15.4%
    IWM
    +11.9%

    Over the past 12 months RNAZ returned -86.5% versus DIA (Dow) +11.6%, SPY (S&P 500) +13.1%, QQQ (Nasdaq 100) +15.4% and IWM (Russell 2000) +11.9%.

    Volume & Liquidity 0.61× 3-mo avg
    Today 32,683 3-mo avg 53.2K
    1W
    25.4K
    1M
    49.2K
    3M
    53.2K
    6M
    57.3K
    YTD
    111.6K
    1Y
    94.2K

    RNAZ most recently traded 32,683 shares against a 3-month average daily volume of 53.2K.

    More News

    Read More
    InvestorNewsBreaks – TransCode Therapeutics, Inc. (NASDAQ: RNAZ) Expands Global Patent Portfolio for RNA-Based Cancer Therapies
    Via Investor Brand Network
    Topics Intellectual Property
    News headline image
    Join Today's Live Investor Webinar with TransCode Therapeutics
    From RedChip Companies, Inc. (Media Suite)
    Via ACCESS Newswire
    NetworkNewsBreaks – TransCode Therapeutics, Inc. (NASDAQ: RNAZ) Names John Tattory Interim CFO Following Tom Fitzgerald Retirement
    Via Investor Brand Network
    Topics Retirement
    News headline image
    Join TransCode Therapeutics' Live Investor Webinar: Advancing a Multi-Platform Oncology Pipeline Targeting Metastatic Cancer
    From RedChip Companies, Inc. (Media Suite)
    Via ACCESS Newswire
    BioMedNewsBreaks — TransCode Therapeutics, Inc. (NASDAQ: RNAZ) Reports TTX-MC138 Survival Benefit in Preclinical Breast Cancer Bone Metastasis Study
    Via Investor Brand Network
    News headline image
    Virax Biolabs and Transcode Therapeutics Interviews to Air Nationally on the RedChip Small Stocks, Big Money(TM) Show on CNBC and Bloomberg TV
    From RedChip Companies, Inc. (Media Suite)
    Via ACCESS Newswire
    News headline image
    12 Health Care Stocks Moving In Monday's After-Market Session ↗
    Via Benzinga
    InvestorNewsBreaks – TransCode Therapeutics, Inc. (NASDAQ: RNAZ) to Host First R&D Webcast Highlighting Phase 2a Oncology Program
    Via Investor Brand Network
    BioMedNewsBreaks — TransCode Therapeutics, Inc. (NASDAQ: RNAZ) Reports Positive Phase 1a Results for TTX-MC138 and Advances Program Toward Phase 2a
    Via Investor Brand Network
    BioMedNewsBreaks — TransCode Therapeutics, Inc. (NASDAQ: RNAZ) Initiates Phase 2a Trial of TTX-MC138 in Colorectal Cancer Patients with Minimal Residual Disease
    Via Investor Brand Network
    InvestorNewsBreaks – TransCode Therapeutics, Inc. (NASDAQ: RNAZ) Appoints Scientific Advisory Board Chair, Signs Research Agreement With Michigan State University
    Via Investor Brand Network
    MissionIRNewsBreaks – TransCode Therapeutics, Inc. (NASDAQ: RNAZ) Secures Up to $20 Million Financing Agreement
    Via Investor Brand Network
    BioMedNewsBreaks – TransCode Therapeutics, Inc. (NASDAQ: RNAZ) Secures Exclusive Global License to Three Unleash Immuno-Oncolytics Drug Candidates
    Via Investor Brand Network
    BioMedNewsBreaks – TransCode Therapeutics, Inc. (NASDAQ: RNAZ) Announces Publication On Tumor-Selective RIG-I Immunotherapy Approach
    Via Investor Brand Network
    BioMedNewsBreaks – TransCode Therapeutics, Inc. (NASDAQ: RNAZ) Submits IND Amendment for Planned Phase 2a Trial of TTX-MC138 in Colorectal Cancer
    Via Investor Brand Network
    BioMedNewsBreaks — TransCode Therapeutics, Inc. (NASDAQ: RNAZ) Publishes Preclinical Data Supporting TTX-MC138 for Glioblastoma
    Via Investor Brand Network
    InvestorNewsBreaks – TransCode Therapeutics, Inc. (NASDAQ: RNAZ) Appoints Jack E. Stover to Board of Directors
    Via Investor Brand Network
    News headline image
    The market is filled with gapping stocks in Thursday's session. ↗
    Via Chartmill
    InvestorNewsBreaks – TransCode Therapeutics, Inc. (NASDAQ: RNAZ) and Quantum Leap Launch Collaboration to Evaluate TTX-MC138 in PRE-I-SPY Trial
    Via Investor Brand Network
    InvestorNewsBreaks – TransCode Therapeutics, Inc. (NASDAQ: RNAZ) Appoints Dr. Michel Janicot as Senior Development Officer
    Via Investor Brand Network
    BioMedNewsBreaks — TransCode Therapeutics, Inc. (NASDAQ: RNAZ) Completes Phase 1a Trial of TTX-MC138, Advancing to Phase 2 Evaluation
    Via Investor Brand Network
    News headline image
    MAGA Stocks Undercard: MYSE, XBIO, ATON, ACXP, RDZN – Innovators Driving Next Tech, Blockchain, AI Wave – More Stocks Inside
    Via AB Newswire
    Topics Artificial Intelligence Intellectual Property
    InvestorNewsBreaks – TransCode Therapeutics, Inc. (NASDAQ: RNAZ) Acquires Polynoma, Secures $25 Million Investment from CK Life Sciences to Advance Phase 2 Trial of TTX-MC138
    Via Investor Brand Network

    Frequently Asked Questions

    Is TransCode Therapeutics, Inc. - Common Stock publicly traded?
    Yes, TransCode Therapeutics, Inc. - Common Stock is publicly traded.
    What exchange does TransCode Therapeutics, Inc. - Common Stock trade on?
    TransCode Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for TransCode Therapeutics, Inc. - Common Stock?
    The ticker symbol for TransCode Therapeutics, Inc. - Common Stock is RNAZ on the Nasdaq Stock Market
    What is the current price of TransCode Therapeutics, Inc. - Common Stock?
    The current price of TransCode Therapeutics, Inc. - Common Stock is 1.770
    When was TransCode Therapeutics, Inc. - Common Stock last traded?
    The last trade of TransCode Therapeutics, Inc. - Common Stock was at 10/23/26 04:00 PM ET
    What is the market capitalization of TransCode Therapeutics, Inc. - Common Stock?
    The market capitalization of TransCode Therapeutics, Inc. - Common Stock is 1.48M
    How many shares of TransCode Therapeutics, Inc. - Common Stock are outstanding?
    TransCode Therapeutics, Inc. - Common Stock has 1M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.